Opko Health Inc.
OPKOpko Health Inc. is a healthcare company specializing in the development of innovative diagnostics and pharmaceuticals. Founded in 2007, the company focuses on personalized medicine, providing diagnostic tests and treatments in areas such as oncology, neurology, and infectious diseases. Its portfolio includes bio-pharmaceutical products, laboratory services, and consumer health products aimed at improving patient outcomes through targeted healthcare solutions.
Company News
Entera Bio's CEO will participate in the Evercore ISI Healthcare Conference, highlighting the company's progress in developing oral peptide therapies for conditions like osteoporosis and hypoparathyroidism.
NextPlat Corp provides an update on its strategic progress across healthcare services, communications, and e-commerce channels, highlighting cost reduction efforts, new contracts, and technology investments aimed at driving growth and profitability.
Entera Bio reported better-than-expected Q2 2025 earnings with a GAAP EPS of $0.06, secured FDA regulatory concurrence for EB613's Phase 3 trial, and maintained a strong cash position of $18.8 million to support operations through mid-Q3 2026.
Opko Health, a significant shareholder in GeneDx Holdings Corp., has sold a portion of its stake in the company, selling 25,000 shares for a total transaction value of approximately $823,187.
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
